Rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori
CA 2115381 C · Owner: Ferrieri, Antonella · Inventors: Rotini, Leone Gabriele; Ferrieri, Antonella
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention refers to the use of the rifamycin antibiotic known by the name of rifaximin (INN) and to pharmaceutical compositions containing it in the oral treatment of the forms of gastric dyspepsia caused by bacteria known as Helicobacter pylori. Rifaximin may be administered in any oral pharmaceutical form particularly tablets, capsules, sugar coated tablets granules and syrups containing from 200 to 2000 mg of active principle at a daily dosage of between 400 and 2000 mg.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 10, 1994 and granted January 5, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 10, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 10, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.